Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Read more: Do insurance plans cover Zepbound
Women should report new menstrual irregularities, though such changes may reflect positive metabolic improvements rather than adverse effects
We know that interest among patients for GLP-1s is high, especially in people trying to lose weight, but injection delivery is one of the key barriers
Healthcare providers increasingly consider Mounjaro for patients who don't achieve desired results with Wegovy or Ozempic
Timeline of Regulatory Milestones 2005: Exenatide (Byetta): First GLP-1 agonist approved, twice-daily injections 2010: Liraglutide (Victoza): Longer-lasting, once-daily injection 2014: Dulaglutide (Trulicity): Once-weekly injection arrives 2017: Semaglutide (Ozempic): First once-weekly injection for diabetes with powerful weight-loss effects 2019: Oral semaglutide (Rybelsus): First GLP-1 pill makes it past the stomachs defenses 2021: High-dose semaglutide (Wegovy): FDA approval for obesity treatment 2022: Tirzepatide (Mounjaro): First dual GLP-1/GIP agonist for diabetes 2023: Tirzepatide (Zepbound): Expanded approval for obesity 20232024 : Widespread shortages: Skyrocketing demand for GLP-1s leads to limited availability The shortage that began in late-2023, driven by soaring off-label demand and supply-chain bottlenecks left millions of patients unable to fill even maintenance scripts
Learn about emerging clinical data and novel mechanisms of action in our module and get practical application strategies for patient care
